Article · Wikipedia archive · Last revised Aug 13, 2026

ABS-201

ABS-201 is an AI-designed monoclonal antibody against the prolactin receptor (PRLR) currently in Phase 1/2a clinical trial for the treatment of androgenic alopecia and endometriosis. It is taken by subcutaneous injection. ABS-201 is a possible first-in-class drug with a novel mechanism of action in the potential treatment of hair loss. ABS-201 is under development by Absci.

Last revised
Aug 13, 2026
Read time
≈ 2 min
Length
438 w
Citations
23
Source
Wikipedia ↗
ABS-201
Clinical data
Other namesABS201
Routes of
administration		Subcutaneous injection1
Drug classProlactin receptor monoclonal antibody
ATC code
  • None

ABS-201 is an AI-designed monoclonal antibody against the prolactin receptor (PRLR) currently in Phase 1/2a clinical trial234 for the treatment of androgenic alopecia (pattern hair loss) and endometriosis.1567 It is taken by subcutaneous injection.16 ABS-201 is a possible first-in-class drug with a novel mechanism of action in the potential treatment of hair loss.8 ABS-201 is under development by Absci.910

It is believed that ABS-201 works by activating dormant hair follicles and causing them to move from the telogen phase to the anagen phase.67 In human ex vivo scalp model studies, ABS-201 stimulated hair regrowth, prolonged anagen phase, blocked catagen phase, inhibited telogen effluvium, and blocked hair from losing color.1112 ABS-201 has been found to produce robust hair regrowth as compared with minoxidil in mice and balding macaques.67

The clinical trial for ABS-201 is being overseen by prominent hair loss researcher Rodney Sinclair,6 one of the principal investigators in minoxidil clinical trials.1314 The chemical structure of the drug does not yet appear to have been disclosed.1

See also

See also

References

References

  1. "ABS 201". AdisInsight. 7 October 2025. Retrieved 14 November 2025.
  2. Absci Pty Ltd. (2025-12-30). A Randomized, Double-Blind, Placebo-Controlled, Phase 1 First-in-Human Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Single and Multiple Ascending Doses of ABS-201 in Healthy Adult Participants With and Without Androgenetic Alopecia (Report). clinicaltrials.gov.
  3. "ABS 201 - Absci - AdisInsight". adisinsight.springer.com. Retrieved 2026-02-05.
  4. "Absci Initiates First-in-Human Trial of AI-Designed Antibody ABS-201 for Hair Loss Treatment". MedPath. 2025-12-04. Retrieved 2026-02-05.
  5. "Delving into the Latest Updates on ABS-201(Absci Corp) with Synapse". Synapse. 25 October 2025. Retrieved 14 November 2025.
  6. Frederickson E (20 October 2025). "A New Hair Loss Drug Could Cure Balding and Reverse Graying". Popular Mechanics. Retrieved 14 November 2025.
  7. Kahn A (2024). "Absci 2024 R&D Day Presentation". Absci Corporation.
  8. "Absci Initiates First-in-Human Trial of AI-Designed Antibody ABS-201 for Hair Loss Treatment". MedPath. 2025-12-04. Retrieved 2026-02-05.
  9. "ABS 201 - Absci - AdisInsight". adisinsight.springer.com. Retrieved 2026-02-05.
  10. "Delving into the Latest Updates on ABS-201(Absci Corp) with Synapse". synapse.patsnap.com. Retrieved 2026-02-05.
  11. "ABS-201 KOL SEMINAR". Absci. December 12, 2025.
  12. "ABS 201 - Absci - AdisInsight". adisinsight.springer.com. Retrieved 2026-02-05.
  13. Applied Biology, Inc. (2018-10-04). Minoxidil Response Testing in Females With Female Pattern Hair Loss (Report). clinicaltrials.gov.
  14. "A 32-week randomized, placebo-controlled, double-blinded pilot study to compare the efficacy and safety of low-dose oral minoxidil in male and female patients with patterned hair loss (androgenetic alopecia) followed by a 24-week open label extension period". MedPath. 2021-11-15. Retrieved 2026-02-05.
External links